Document Type : Short Communication
Authors
- Umid Sanjarovich Akbarov
- Tamara Uktamovna Aripova
- Adolat Abdurahimovna Ismailova
- A’zam Akbar Ug’li Rakhimjonov
- Larisa Viktorovna Sher
- Tatyana Aleksandrovna Petrova
- Muxlisa Saidakbarhojaevna Kasimova
- Dildora Sobirjon Qizi Karimova
- Ramazan Joldasbaevich Rozumbetov
Institute of Immunology and Human Genomics, Academy of Science of Republic of Uzbekistan, Tashkent, Uzbekistan
Abstract
The COVID-19 pandemic has become a big challenge for the health systems of all countries. Since there were no reliable data on the efficacy of various drugs for COVID-19 in the early months of the pandemic, medical staff had to rely on constantly changing temporary recommendations and their experience in managing patients with COVID-19. In this regard, it is important to study the actions of medical personnel in a pandemic. In this study, we investigated the administration of drugs to treat COVID-19 in Uzbekistan. We demonstrated that physicians were swiftly adapting to new therapy recommendations; however, some drugs were not used appropriately, e.g., antibiotics and dexamethasone.
Keywords
- Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents. 2020 Mar;55(3):105924. doi: 10.1016/j.ijantimicag.2020.105924. PMID: 32081636. PMCID: PMC7127800.
- World Health Organization. COVID-19 Weekly Epidemiological Update Global Overview Update 15 june. (2022).
- Echeverría-Esnal D, Martin-Ontiyuelo C, Navarrete-Rouco ME, De-Antonio Cuscó M, Ferrández O, Horcajada JP, et al. Azithromycin in the treatment of COVID-19: a review. Expert Rev Anti Infect Ther. 2021 Feb;19(2):147-163. doi: 10.1080/14787210.2020.1813024. PMID: 32853038.
- Ministry of healthcare of the Republic of Uzbekistan. Practical recommendations for the management of patients infected with COVID-19. 2020.
- Abaleke, E. et al. Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet 2021. 397, 605–612. doi: 1016/S0140-6736(21)00149-5. PMID: 33545096; PMCID: PMC7884931.
- Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020 Mar 18;6:16. doi: 10.1038/s41421-020-0156-0. PMID: 32194981. PMCID: PMC7078228.
- Statement from the Chief Investigators of the Randomised Evaluation of COVid-19 thERapY (RECOVERY) Trial on hydroxychloroquine. No clinical benefit from use of hydroxychloroquine in hospitalised patients with COVID. www.recoverytrial.net. (2020).
- Flumignan RL, Civile VT, Tinôco JDS, Pascoal PI, Areias LL, Matar CF, Tendal B, Trevisani VF, Atallah ÁN, Nakano LC. Anticoagulants for people hospitalised with COVID-19. Cochrane Database Syst Rev. 2022 Mar 4;3(3):CD013739. doi: 10.1002/14651858.CD013739. PMID: 35244208. PMCID: PMC8895460.
- The RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19. New England Journal of Medicine 384, 693–704 (2021). doi:10.1056/NEJMoa2021436.
- World Health Organization. Guideline Clinical management of COVID-19 patients: living guideline, 23 june 2022. http://apps.who.int/bookorders. (2021).
)